This clinical trial is being conducted in Hypophosphatasia, a bone disorder caused by gene mutation(s) resulting in bone defects. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study is to provide access to treatment in a disease where no approved treatment exists. This is an experimental treatment provided under specific treatment guidelines in which safety endpoints will be collected.
U.S. sites participating in the expanded access program are closed to enrollment.
Biological: asfotase alfa
Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
Inclusion Criteria
Patients must meet all of the following inclusion criteria for participation in this
program:
1. Patient or parent (or legal guardian) must provide written informed consent prior to
the performance of any program-related procedures and must be willing to comply with
program procedures. Where appropriate and required by local regulations, patient
assent for participation must also be obtained.
2. Patient must have a documented diagnosis of HPP as indicated by a documented history
of HPP-related skeletal abnormalities and one or more of the following:
- Documented tissue-nonspecific alkaline phosphatase (TNSALP) gene mutation(s)
- Serum alkaline phosphatase (ALP) level below the age-adjusted normal range AND
plasma pyridoxal-5'-phosphate (PLP) above the upper limit of normal at Screening.
NOTE: Historical results for PLP may be used to determine patient eligibility.
The criterion for plasma PLP is not applicable if the patient is receiving
pyridoxine treatment.
3. Patient must have infantile- or juvenile-onset HPP, defined as documented onset of
signs/symptoms of HPP prior to 18 years of age.
4. Male patient is:
- Prepubertal; OR
- Surgically sterile (defined as vasectomized for ≥6 months at Baseline); OR
- Non-surgically sterile (defined as non-vasectomized or vasectomized for <6 months
at Baseline) and his female spouse/partner who is of childbearing potential must
be using highly effective contraception consisting of two forms of birth control
(at least one of which must be a barrier method) as described below starting at
Baseline and continuing for 3 months after program completion.
- Simultaneous use of condom, and for the female partner established use of
hormonal contraceptives (eg, oral, injected, implanted) or intra-uterine
contraceptive device
- Simultaneous use of condom, and for the female partner occlusive cap
(diaphragm or cervical/vault caps) with intravaginally applied spermicide
5. Female patient is:
- Of non-childbearing potential, defined as:
- Prepubertal; OR
- Post-menopausal (defined as absence of menses for 12 months prior to
Baseline or bilateral oophorectomy or hysterectomy with bilateral
oophorectomy at least 6 months prior to Baseline); OR
- Surgically sterile (defined as having hysterectomy or tubal ligation at
least 6 months prior to Baseline) OR
- Of childbearing potential, and:
- Not sexually active; OR
- Sexually active with non-sterile male spouse/partner (sterile male
spouse/partner defined as a man vasectomized for ≥6 months) and must be
using highly effective contraception consisting of two forms of birth
control (at least one of which must be a barrier method) as described below
and continuing for 3 months after program completion.
- Simultaneous use of hormonal contraceptives (eg, oral, injected, implanted)
or intra-uterine contraceptive device since at least 4 weeks prior to
Baseline, and condom for the male partner
- Simultaneous use of occlusive cap (diaphragm or cervical/vault caps) with
intravaginally applied spermicide, and a condom for the male partner, since
at least 14 days prior to Baseline
6. Male patients who are pubertal or post-pubertal and not surgically sterile (surgically
sterile defined as vasectomized for ≥6 months) must agree to not donate sperm during
program participation and for 3 months after program completion.
7. Female patients of childbearing potential (ie, those who are not prepubertal or
postmenopausal or surgically sterile as defined in inclusion criteria 5 above) must
have a negative urine or serum pregnancy test at Screening.
Exclusion Criteria
Patients will be excluded from participation in this program if they meet one or more of
the following exclusion criteria:
1. Patient has geographic access to and qualifies for enrollment (as determined by the
Sponsor and Investigator) in any other Alexion-sponsored clinical trials of asfotase
alfa that are open to enrollment (eg, ENB-010-10).
2. Patient is pregnant, trying to become pregnant, or is lactating.
3. Patient has a documented sensitivity to any of the components of asfotase alfa.
4. Patient has serum calcium and/or phosphorus levels below the normal range at
Screening.
5. Patient is currently enrolled in any other program or study involving an
investigational new drug, device, or treatment for HPP (eg, bone marrow
transplantation).
6. Patient has any other medical condition, serious intercurrent illness, or other
extenuating circumstance that, in the opinion of the Investigator, may significantly
interfere with program compliance, including all evaluations and follow-up activities.
Patients who previously received treatment with asfotase alfa may be considered for
enrollment.
Colorado Center for Bone Research
Lakewood, Colorado, United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Hôpital Necker - Enfants Malades
Paris, France
Hôpital des Enfants
Toulouse Cedex 9, France
Andrew Denker, MD, PhD, Study Director
Medical Monitor